An overview on inactivated and live‐attenuated SARS‐CoV‐2 vaccines

Journal of Clinical Laboratory Analysis, Год журнала: 2022, Номер 36(5)

Опубликована: Апрель 14, 2022

Abstract After about 2 years since severe acute respiratory syndrome coronavirus (SARS‑CoV‑2), first infections were detected in Wuhan city of China December 2019, which was followed by a worldwide pandemic with record 5.41 million deaths. Due to urgent need for the development safe and effective vaccine disease 2019 (COVID‐19), attempts producing efficient vaccines are inexhaustibly continuing. According report World Health Organization (WHO) on COVID‐19 tracker landscape, there 149 candidates all over world. Inactivated SARS‐CoV‐2 as conventional platform consist whole virus particles grown cell culture inactivated chemicals. Because benefits such antigenic similarity real virion inducing humoral cellular immune responses ease transport storage, these vaccines, including produced Bharat Biotech, Sinopharm, Sinovac, use at large scales. In this study, we have review that passing their phase 3 4 clinical trials, population included producers, efficiency, adverse effects, components other features.

Язык: Английский

---

Adverse effects following COVID-19 vaccination in Iran

BMC Infectious Diseases, Год журнала: 2022, Номер 22(1)

Опубликована: Май 18, 2022

Vaccination is a key intervention to prevent COVID-19. Many vaccines are administered globally, yet there not much evidence regarding their safety and adverse effects. Iran also faces this challenge, especially as data the Sputnik V vaccine sparse. Therefore, aim of study determine effects most commonly used in Iran.Using retrospective cohort design, 6600 subjects aged 18 years or older who had received two doses any three COVID-19 (Sinopharm, AstraZeneca, V) were selected using random sampling method between March August 2021. Subjects asked about by trained interviewers via telephone interview. Vaccine-related individuals during first 72 h subsequently following both determined. The demographic variables, type vaccine, effects, history previous infection with collected. Descriptive statistics (mean, standard deviation) analytical (Chi-squared Wilcoxon tests) performed at 95% significance level STATA software version 15 (STATA Corp, College Station, TX, USA).From participants, 4775 responded (response rate = 72.3%). Of 1460 (30.6%) AstraZeneca 1564 (32.8%) Sinopharm 1751 (36.7%) vaccine. 2653 participants (55.56%) reported after dose 1704 (35.7%) second dose. caused 1449 (82.7%) recipients reporting symptoms dose, compared 1030 (70.5%) for only 585 (37.4%) common fatigue (28.37%), chill/fever (26.86%), skeletal pain (22.38%). These same although prevalence was lower.In study, we demonstrate that has highest followed vaccines. safe no reports serious

Язык: Английский

---

The Side Effects and Adverse Clinical Cases Reported after COVID-19 Immunization

Vaccines, Год журнала: 2022, Номер 10(4), С. 488 - 488

Опубликована: Март 22, 2022

COVID-19 remains a deadly disease that poses serious threat to humanity. vaccines protect the public and limit viral spread. However, acceptance is significantly dependent on efficacy side effects (SEs) of vaccinations being produced. Four important mechanisms have been examined for vaccines: DNA-based, mRNA-based, protein-based, inactivated viruses. Vaccination safety research was formerly limited manufacturer-sponsored studies, but numerous additional cross-sectional survey-based studies conducted globally contributed generation vaccine-related data reports. Twenty-seven twenty-four case reports published-up till 2021 were overviewed presentation SEs their severity. Injection site pain remained most dominant localized SE, while headache fatigue prevalent systemic SEs. Most reported all safe, with very little or no adverse effects, nature be more persistent in DNA- mRNA-based vaccines, associated longer-duration Overall, found women youngsters. Case reactions also documented, there still need find out pathological linkage vaccination.

Язык: Английский

---

Side Effects of COVID-19 Inactivated Virus vs. Adenoviral Vector Vaccines: Experience of Algerian Healthcare Workers

Frontiers in Public Health, Год журнала: 2022, Номер 10

Опубликована: Май 16, 2022

Healthcare workers were prioritized in vaccination campaigns globally because they are exposed to the highest risk of contamination by SARS-CoV-2. This study evaluated self-reported post-vaccination side effects inactivated (BBIBP-CorV and CoronaVac) adenoviral vector-based (AZD1222, Gam-COVID-Vac Ad26.COV2.S) vaccines among Algerian healthcare using a validated questionnaire. The final analysis included 721 workers, with predominance females (59.1%) younger individuals 20–30 years old (39.4%). Less than half (49.1%) respondents reported at least one local effect, while 53.8% systemic effect. These more prevalent viral vector vaccinees virus vaccinees. most common injection site pain (39%) arm (25.4%), fatigue (34.4%), fever (28.4%), headache (24.8%) myalgia (22.7%) effects. appeared earlier recipients generally lasted for 2 3 days two vaccinated groups. factors associated higher prevalence female gender, allergic individuals, regular medication, those who contracted COVID-19 disease received doses both viral-based Despite recipients, groups equally effective preventing symptomatic infections, no life-threatening either vaccine group.

Язык: Английский

---

COVID-19 Therapeutics: Use, Mechanism of Action, and Toxicity (Vaccines, Monoclonal Antibodies, and Immunotherapeutics)

Journal of Medical Toxicology, Год журнала: 2023, Номер 19(2), С. 205 - 218

Опубликована: Март 2, 2023

Язык: Английский

---

Extension and Severity of Self-Reported Side Effects of Seven COVID-19 Vaccines in Mexican Population

Frontiers in Public Health, Год журнала: 2022, Номер 10

Опубликована: Март 14, 2022

A few studies examined the comparative side effects of Coronavirus Disease-19 (COVID-19) vaccines. We compared extension and severity self-reported seven COVID-19 vaccines [BNT162b2 (Pfizer-BioNTech), ChAdOx1 (AstraZeneca), mRNA-1273 (Moderna), CoronaVac (Sinovac Life Sciences), Gam-COVID-Vac (Gamaleya's Sputnik V), Ad5-nCoV (CanSinoBIO), Ad26.CoV2.S (Johnson & Johnson/Janssen)] in Mexican population. also evaluated association type vaccine, sex, age, comorbidity, history allergies to extent effects. This was a cross-sectional study carried out online between August 12 September 3, 2021 Mexico. The first inclusion criterion receive vaccine second, being at least 18 years old. survey link distributed via multiple social media platforms. questioned about symptoms based on short-term reported literature. Side effect classified as local, systemic, or both. asked need take medicine, stop activities/miss work, seek medical attention. Then, index constructed responses. Descriptive stepwise multivariate logistic ordinal regression analyses were used calculate odds ratio (OR) 95% CI for each outcome adjusted by potential confounders. mean age 38.9 ± 11.0 ( n = 4,024). Prevalence one varied number doses. At dose 1, with highest rate (85%) followed (80%). Both associated greater (adjusted OR 2.53, 2.16, 2.96 2.41, 1.76, 3.29, respectively) 4.32, 3.73, 5.00 3.00, 2.28, 3.94, respectively). Young (<50 years), female severity, independent 2, (88%) only 2.88, 1.59, 5.21) 3.14, 1.82, 5.43). Continuous are necessary acknowledge more post-vaccine different populations.

Язык: Английский

---

Inactivated vaccine Covaxin/BBV152: A systematic review

Frontiers in Immunology, Год журнала: 2022, Номер 13

Опубликована: Авг. 9, 2022

We systematically reviewed and summarized studies focusing on Bharat Biotech's Whole Virion Inactivated Corona Virus Antigen BBV152 (Covaxin), which is India's indigenous response to fighting the SARS-CoV-2 pandemic. Studies were searched for data efficacy, immunogenicity, safety profile of BBV152. All relevant published up March 22, 2022, screened from major databases, 25 eventually inducted into systematic review. The focused virus antigen (6 μg) adjuvanted with aluminium hydroxide gel and/or Imidazo quinolin gallamide (IMDG), aTLR7/8 agonist. Pre-clinical, phase I, II clinical trials showed appreciable immunogenicity. Both neutralizing binding antibody titers significant T cell responses Th1-biased. Phase III 6 μg +Algel-IMDG formulation a 93.4% efficacy against severe COVID-19. Data revealed an acceptable mostly mild-moderate local systemic adverse events. No serious events or fatalities seen, most reported milder lesser Covaxin when compared other vaccines, especially Oxford-Astra Zeneca's AZD1222 (Covishield). immunogenicity performance Covaxin, provided protection only after second dose, was mediocre it consistently surpassed by Covishield. One study adjusted effectiveness symptomatic infection be just 50% at 2 weeks dose. Nonetheless, results seen in previously infected individuals administered both doses. There some evidence coverage Alpha, Beta, Delta variants. However, neither nor Covishield sufficient Omicron variant. Two super-additive mixing Further exploration heterologous prime-boost vaccination combination inactivated vaccine adenoviral vector-based tackling future variants may beneficial.

Язык: Английский

---

Sputnik-V reactogenicity and immunogenicity in the blood and mucosa: a prospective cohort study

Scientific Reports, Год журнала: 2022, Номер 12(1)

Опубликована: Авг. 1, 2022

Abstract Sputnik-V (Gam-COVID-Vac) is a heterologous, recombinant adenoviral (rAdv) vector-based, COVID-19 vaccine now used in > 70 countries. Yet there shortage of data on this vaccine's performance diverse populations. Here, we performed prospective cohort study to assess the reactogenicity and immunologic outcomes vaccination Kazakhstan. COVID-19-free participants (n = 82 at baseline) were followed day 21 after dose 1 (rAd5) 2 (rAd26). Self-reported local systemic adverse events captured using questionnaires. Blood nasopharyngeal swabs collected perform SARS-CoV-2 diagnostic assays. We observed that most reported mild-to-moderate injection site or reactions, no severe potentially life-threatening conditions reported, appeared be more reactogenic than 2. The seroconversion rate was 97% post-dose 1, remaining same proportion with detectable virus neutralization 83% increasing 98% 2, largest relative increase without prior exposure. Dose boosted nasal S-IgG S-IgA, while boosting effect mucosal S-IgG, but not only subjects COVID-19. Systemically, reduced serum levels growth regulated oncogene (GRO), which correlated an elevation blood platelet count. Overall, elicited both immunity, immune minimal. Thus, adjustments current dosing regimen are necessary optimize immunization efficacy cost-effectiveness. While similar other vaccines, induced alterations GRO/platelet axis warrant investigation vaccine’s effects immunology.

Язык: Английский

---

Evaluation of COVID-19 vaccination status and immune response among staff at Shahid Motahari Hospital, Urmia, 2021

Health Science Monitor, Год журнала: 2025, Номер 4(1), С. 7 - 14

Опубликована: Фев. 1, 2025

Язык: Английский

---

Prevalence and pattern of adverse events following COVID-19 vaccination among adult population in Sokoto metropolis, northwest, Nigeria

PLoS ONE, Год журнала: 2025, Номер 20(3), С. e0277585 - e0277585

Опубликована: Март 12, 2025

Background COVID-19 still poses a major public health challenge worldwide and vaccination remains one of the interventions to control disease. Different types vaccines approved by World Health Organization (WHO) are currently in use across world protect against This study assessed prevalence pattern adverse events following immunization (AEFI) after receiving vaccine (the Oxford-AstraZeneca vaccine) among adult population Sokoto metropolis, North-west, Nigeria. Methods We conducted cross-sectional 230 adults metropolis who received vaccines. Data was collected using structured questionnaire administered via personal phone calls respondents were selected systematic sampling technique. For data analysis, IBM SPSS version 25.0 used. Results The majority participants [183 (79.7%)] experienced AEFI. most common body weakness [157 (85%)], fever [111 (60.3%)] headache [103 (56%)]. Up half that AEFI said it occurred within minutes few hours, whereas 75 (40.8%) 2-3 days. 66.3% reactions mild lasted between hours (37.5%) day (31.5%); however, 15.2% had severe which 22.7% admitted facility. development linked presence an underlying medical condition (p = 0.001), previous history 0.017), drug reaction 0.005). Conclusion reported with vaccine; weakness, fever, being AEFIs. History as well predictors vaccination. Service providers at each point should always take time explain recipients possible; they reassure them ARs resolve

Язык: Английский

---